LT2016100A - Dimeric antibody fragment neutralizing cytolytic activity of vaginolysin - Google Patents
Dimeric antibody fragment neutralizing cytolytic activity of vaginolysinInfo
- Publication number
- LT2016100A LT2016100A LT2016100A LT2016100A LT2016100A LT 2016100 A LT2016100 A LT 2016100A LT 2016100 A LT2016100 A LT 2016100A LT 2016100 A LT2016100 A LT 2016100A LT 2016100 A LT2016100 A LT 2016100A
- Authority
- LT
- Lithuania
- Prior art keywords
- vaginolysin
- neutralizing
- antibody fragment
- dimeric antibody
- cytolytic activity
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 2
- 230000001461 cytolytic effect Effects 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract 1
- 241000207201 Gardnerella vaginalis Species 0.000 abstract 1
- 208000037009 Vaginitis bacterial Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
New dimeric antibody fragments against vaginolysin were constructed by genetic methods and purified. They effectively neutralize the cytolytic effect of vaginolysin on human cells and can be used for prophylaxis and/or treatment of bacterial vaginosis caused by Gardnerella vaginalis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2016100A LT6389B (en) | 2016-10-03 | 2016-10-03 | DIMENSIONAL ANTI-BODY FRAGMENT WHICH DOES NOT REALIZE VAGINOLIC CITOLITIC ACTIVITY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT2016100A LT6389B (en) | 2016-10-03 | 2016-10-03 | DIMENSIONAL ANTI-BODY FRAGMENT WHICH DOES NOT REALIZE VAGINOLIC CITOLITIC ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2016100A true LT2016100A (en) | 2017-04-10 |
| LT6389B LT6389B (en) | 2017-05-10 |
Family
ID=58463981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2016100A LT6389B (en) | 2016-10-03 | 2016-10-03 | DIMENSIONAL ANTI-BODY FRAGMENT WHICH DOES NOT REALIZE VAGINOLIC CITOLITIC ACTIVITY |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT6389B (en) |
-
2016
- 2016-10-03 LT LT2016100A patent/LT6389B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| LT6389B (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122344T1 (en) | BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| MX376691B (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN IL-4R ANTAGONIST FOR TREATMENT OF A SKIN INFECTION. | |
| MX2021006581A (en) | Bacteria engineered to treat diseases associated with hyperammonemia. | |
| MX2021007003A (en) | METHOD TO TREAT CANCER. | |
| EP4299122A3 (en) | Compositions and methods for treating skin and mucous membrane diseases | |
| MX381283B (en) | PEMPHIGUUS TREATMENT. | |
| MX2022010623A (en) | Treatment of cancer using anti-cd19 chimeric antigen receptor. | |
| MX2020009780A (en) | Autotaxin inhibitor compounds. | |
| MX389560B (en) | COMBINATION IMMUNOTHERAPY APPROACH TO CANCER TREATMENT. | |
| GB2541571A (en) | Pharmaceutical compositions | |
| NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
| EA201691845A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| MX2018002067A (en) | Tetracycline management of egfr inhibitor associated dermatoses. | |
| EA201691844A1 (en) | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS | |
| PH12015500114A1 (en) | HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF | |
| PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2015008486A (en) | Compositions and methods for treating bacterial infections. | |
| AU2016323967A8 (en) | Compositions and methods for the treatment and prevention of radiation dermatitis | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| TN2015000409A1 (en) | Rifaximin for use in the treating of vaginal infections | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| HK40046229A (en) | Methods and compositions for treating skin disease with recombinant microorganisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Patent application published |
Effective date: 20170410 |
|
| FG9A | Patent granted |
Effective date: 20170510 |
|
| MM9A | Lapsed patents |
Effective date: 20191003 |